Miglitol attenuates non-alcoholic steatohepatitis in diabetic patients.

Michiharu KomatsuNaoki TanakaTakefumi KimuraNaoyuki FujimoriKenji SanoAkira HoriuchiAyumi SugiuraTomoo YamazakiSoichiro ShibataSatoru JoshitaTakeji UmemuraAkihiro MatsumotoEiji Tanaka

Published in: Hepatology research : the official journal of the Japan Society of Hepatology (2018)

Miglitol appears to safely ameliorate NASH activity by attenuation of steatosis and lobular/portal inflammation. Appropriately powered controlled trials are warranted to validate our results.

Keyphrases

oxidative stress
insulin resistance
high fat diet
liver injury
high fat diet induced
adipose tissue
metabolic syndrome